Actively Recruiting
Comparing Once-Daily Oral Orforglipron and Once-Weekly Dulaglutide in Children and Teens 10 to 17 Years with Type 2 Diabetes A Phase 3 Randomized Treatment Study
Led by Eli Lilly and Company · Updated on 2026-10-19
170
Participants Needed
71
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the medicine orforglipron compared to dulaglutide in children and teenagers aged 10 to less than 18 years who have type 2 diabetes. The study aims to understand how well these medicines work, how safe they are, and how the body processes them. This trial is a Phase 3 randomized study that focuses on treatment for pediatric participants with this condition. Participants will be randomly assigned to receive either orforglipron orally once daily or dulaglutide by subcutaneous injection once weekly. The study treatment period lasts about 40 weeks, with monitoring extending up to 61 weeks. Both medicines are being assessed for their effects on blood sugar control and other health measures during this time. Participants will be involved in regular visits for evaluations, including blood tests to measure hemoglobin A1c and other health indicators such as body weight, blood pressure, and cholesterol. Researchers will also monitor safety and how the medicines are processed in the body. Overall participation in the study will last approximately 61 weeks, during which participants will receive ongoing assessments to track treatment outcomes.
CONDITIONS
Brief Title
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here